Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019 : The RECUR England study
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: To generate real-world evidence on all-cause mortality and economic burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England.
METHODS: We conducted a cohort study using retrospective data from Clinical Practice Research Datalink linked to Hospital Episode Statistics. Patients diagnosed with CDI in hospital and community settings during 2015-2018 were included and followed for ≥1 year. All-cause mortality was described at 6, 12, and 24 months. Healthcare resource usage (HCRU) and associated costs were assessed at 12 months of follow-up. A cohort of non-CDI patients, matched by demographic and clinical characteristics including Charlson Comorbidity Index score, was used to assess excess mortality and incremental costs of HCRU.
RESULTS: All-cause mortality among CDI patients at 6, 12, and 24 months was 15.87%, 20.37%, and 27.03%, respectively. A higher proportion of rCDI patients died at any point during follow-up. Compared with matched non-CDI patients, excess mortality was highest at 6 months with 1.81 and 2.53 deaths per 100 patient-months among CDI and ≥1 rCDI patients. Hospitalizations were the main drivers of costs, with an incremental cost of £1209.21 per CDI patient. HCRU and costs increased with rCDIs.
CONCLUSION: CDI poses a substantial mortality and economic burden, further amplified by rCDIs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:142 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 142(2024) vom: 18. Apr., Seite 106967 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghosh, Subrata [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clostridioides difficile |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2024.02.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368589870 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368589870 | ||
| 003 | DE-627 | ||
| 005 | 20240416232549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240219s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2024.02.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM368589870 | ||
| 035 | |a (NLM)38368927 | ||
| 035 | |a (PII)S1201-9712(24)00037-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghosh, Subrata |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019 |b The RECUR England study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: To generate real-world evidence on all-cause mortality and economic burden of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in England | ||
| 520 | |a METHODS: We conducted a cohort study using retrospective data from Clinical Practice Research Datalink linked to Hospital Episode Statistics. Patients diagnosed with CDI in hospital and community settings during 2015-2018 were included and followed for ≥1 year. All-cause mortality was described at 6, 12, and 24 months. Healthcare resource usage (HCRU) and associated costs were assessed at 12 months of follow-up. A cohort of non-CDI patients, matched by demographic and clinical characteristics including Charlson Comorbidity Index score, was used to assess excess mortality and incremental costs of HCRU | ||
| 520 | |a RESULTS: All-cause mortality among CDI patients at 6, 12, and 24 months was 15.87%, 20.37%, and 27.03%, respectively. A higher proportion of rCDI patients died at any point during follow-up. Compared with matched non-CDI patients, excess mortality was highest at 6 months with 1.81 and 2.53 deaths per 100 patient-months among CDI and ≥1 rCDI patients. Hospitalizations were the main drivers of costs, with an incremental cost of £1209.21 per CDI patient. HCRU and costs increased with rCDIs | ||
| 520 | |a CONCLUSION: CDI poses a substantial mortality and economic burden, further amplified by rCDIs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clostridioides difficile | |
| 650 | 4 | |a England | |
| 650 | 4 | |a Healthcare costs | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a RECUR | |
| 650 | 4 | |a Recurrence | |
| 700 | 1 | |a Antunes, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Rinta-Kokko, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Chaparova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Lay-Flurrie, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Tricotel, Aurore |e verfasserin |4 aut | |
| 700 | 1 | |a Andersson, Fredrik L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 142(2024) vom: 18. Apr., Seite 106967 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:2024 |g day:18 |g month:04 |g pages:106967 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2024.02.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 2024 |b 18 |c 04 |h 106967 | ||